<DOC>
	<DOCNO>NCT01651351</DOCNO>
	<brief_summary>The purpose study generate sufficient safety tolerability information support increase infusion rate intravenous GLASSIA prescribe information 0.04 0.2 mL/kg/min .</brief_summary>
	<brief_title>GLASSIA Infusion Rate Study</brief_title>
	<detailed_description>To achieve proper masking , 30 participant randomly assign receive either GLASSIA 0.04 mL/kg/min simultaneous administration placebo ( 2.5 % human albumin normal saline ) 0.2 mL/kg/min ( Cohort 1 ) GLASSIA 0.2 mL/kg/min simultaneous administration placebo 0.04 mL/kg/min ( Cohort 2 ) Day 1 . Two week later ( Day 15 ) , participant receive second infusion opposite rate GLASSIA infusion correspond mask placebo infusion .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Male female , 18 65 year age inclusive , time screen Body mass index ( BMI ) range 19.0 32.0 kg/m2 ( inclusive ) body weight &gt; = 50 kg time screen Healthy subject clinical evidence acute and/or chronic disease clinically significant abnormality hematology panel , clinical chemistry panel , urinalysis , electrocardiogram ( ECG ) time screen Negative drug screen test screening . Subject must agree refrain heavy alcohol consumption ( defined 2 drink per day regular basis ) use narcotic drug illegal substance least 2 week prior screen throughout course study . Subject must also agree drug screen test discretion investigator time course study . If female childbearing potential , subject present negative serum pregnancy test agree employ adequate birth control measure duration study If male , subject must agree use acceptable form birth control throughout study least 90 day dose . Additionally , subject must agree abstain sperm donation 90 day last administration investigational product . Subject willing able comply requirement protocol Known history OR positive serological evidence time screen hepatitis A virus ( HAV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , Parvovirus B19 ( PVB19 ) human immunodeficiency virus ( HIV ) type 1/2 infection Known history hypersensitivity adverse reaction ( e.g . urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow administration blood blood component Documented immunoglobulin A ( IgA ) deficiency ( &lt; 7 mg/dL screen ) Evidence uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg , and/or diastolic blood pressure &gt; 100 mm Hg despite antihypertensive medication ) Subject nurse intend begin nurse course study Subject participate clinical trial receive investigational product within 60 day prior screen Subject plan medical procedure within study period Any clinically significant medical , psychiatric , cognitive illness recreational drug/alcohol use , opinion investigator , may impede subject 's ability comply study procedure , pose increase risk subject 's safety , confound interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Condition :</keyword>
	<keyword>study</keyword>
	<keyword>Focus</keyword>
	<keyword>volunteer</keyword>
</DOC>